Benzinga - by Avi Kapoor, Benzinga Staff Writer.
U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday.
Shares of Intel Corporation (NASDAQ: INTC) fell sharply in today’s pre-market trading after the company outlined a new financial framework for its foundry business.
After the market close on Tuesday, Intel announced a new financial reporting structure designed to drive increased cost discipline and higher returns by providing greater transparency, accountability and incentives across the business.
Intel shares dipped 4.8% to $41.85 in pre-market trading.
- Here are some big stocks recording losses in today’s pre-market trading session.
- Mesoblast Limited (NASDAQ: MESO) shares tumbled 13.1% to $5.73 in pre-market trading after gaining 8% on Tuesday.
- Fractyl Health, Inc. (NASDAQ: GUTS) fell 9.1% to $6.13 in pre-market trading after declining around 10% on Tuesday. The company recently announced FDA IDE approval for the Revita Remain-1 pivotal study and then rebounded after reporting Q4 financial results.
- Nikola Corporation (NASDAQ: NKLA) shares declined 7.3% to $0.9027 in pre-market trading after falling more than 5% on Tuesday.
- Nuvation Bio Inc. (NYSE: NUVB) shares fell 5.8% to $3.25 in pre-market trading after declining over 6% on Tuesday. Nuvation Bio, last week, announced appointment of Colleen Sjogren as Chief Commercial Officer.
- Shinhan Financial Group Co., Ltd. (NYSE: SHG) shares declined 5.6% to $31.47 in pre-market trading.
- XPeng Inc. (NYSE: XPEV) shares fell 3.2% to $7.35 in pre-market trading. XPeng recently said it delivered 9,026 Smart EVs in March, representing a 99% increase over the prior month and a 29% increase year-over-year.
- Li Auto Inc.(NASDAQ: LI) shares fell 3% to $ 30.11 in pre-market trading. Li Auto recently reported March vehicle deliveries of 28,984, an increase of 39.2% year over year.
Now Read This: Acuity Brands, Cal-Maine Foods And 3 Stocks To Watch Heading Into Wednesday
Don’t forget to check out our premarket coverage here
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.